Steven R. Feldman, Ran Gao, Rhonda L. Bohn, Stephani Gray, Anouk Déruaz-Luyet, Jashin J. Wu
{"title":"Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study","authors":"Steven R. Feldman, Ran Gao, Rhonda L. Bohn, Stephani Gray, Anouk Déruaz-Luyet, Jashin J. Wu","doi":"10.1007/s12325-025-03122-w","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Palmoplantar pustulosis (PPP) is a debilitating skin condition characterized by pustules, erythema, and scales on the palms and soles. Treatment adherence in psoriatic diseases is suboptimal.</p><h3>Methods</h3><p>A retrospective cohort study, using healthcare claims data from patients aged ≥ 18 years with newly diagnosed PPP (selected between October 1, 2016 and March 31, 2020 from IBM<sup>®</sup> MarketScan<sup>®</sup> Commercial and the Optum<sup>®</sup> Clinformatics<sup>®</sup> Data Mart databases), was conducted to investigate adherence to and persistence with biologics in patients with PPP.</p><h3>Results</h3><p>Biologics were dispensed to 114/840 (13.6%) MarketScan and 76/750 (10.1%) Optum patients. Mean proportion of days covered (PDC; range) for biologics was similar between databases (MarketScan, 66% [8–100%]; Optum, 61% [8–99%]), and good adherence (≥ 80% PDC) was infrequent (MarketScan, 42.1%; Optum, 34.2%). Mean (standard deviation) persistence was slightly longer in MarketScan (283 [121] days) versus Optum (275 [133] days). Mean (range) adherence was similar between ages, although persistence was longer in patients aged 18–64 versus ≥ 65 years (279 [132] vs 258 [140] days).</p><h3>Conclusion</h3><p>In patients with PPP, adherence to biologics was poor and persistence was variable; understanding and addressing the reasons behind these observations may improve treatment outcomes.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 4","pages":"1994 - 2002"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03122-w.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03122-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Palmoplantar pustulosis (PPP) is a debilitating skin condition characterized by pustules, erythema, and scales on the palms and soles. Treatment adherence in psoriatic diseases is suboptimal.
Methods
A retrospective cohort study, using healthcare claims data from patients aged ≥ 18 years with newly diagnosed PPP (selected between October 1, 2016 and March 31, 2020 from IBM® MarketScan® Commercial and the Optum® Clinformatics® Data Mart databases), was conducted to investigate adherence to and persistence with biologics in patients with PPP.
Results
Biologics were dispensed to 114/840 (13.6%) MarketScan and 76/750 (10.1%) Optum patients. Mean proportion of days covered (PDC; range) for biologics was similar between databases (MarketScan, 66% [8–100%]; Optum, 61% [8–99%]), and good adherence (≥ 80% PDC) was infrequent (MarketScan, 42.1%; Optum, 34.2%). Mean (standard deviation) persistence was slightly longer in MarketScan (283 [121] days) versus Optum (275 [133] days). Mean (range) adherence was similar between ages, although persistence was longer in patients aged 18–64 versus ≥ 65 years (279 [132] vs 258 [140] days).
Conclusion
In patients with PPP, adherence to biologics was poor and persistence was variable; understanding and addressing the reasons behind these observations may improve treatment outcomes.
期刊介绍:
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.